Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide vs Sitagliptin in T2DM with Renal Impairment (HARMONY 8)
NCT01098539Phase 3Completed
- Sponsor
- GSK
- Start
- May 2010
- Primary completion
- Nov 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of albiglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 weeks. Started May 2010; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01098539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01098539.